Loading…
5 companies · GEL, thousands · columns ordered by revenue
GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series
| Metric | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,525 | 10,652 | 8,734 | 10,010 | 11,613 | 10,440 | 6,823 | 3,484 |
| EBITDA | 1,416 | 857 | 247 | 383 | 97 | -316 | -1,010 | -66 |
| Net profit | -427 | 8,879 | -62 | -184 | 40 | 44 | -1,206 | -227 |
| Total assets | 22,216 | 17,311 | 6,517 | 7,362 | 6,416 | 5,677 | 5,905 | 5,486 |
| n (companies reporting) | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 |
GEL, thousands
| Company | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| Pip Company | 0 | 1,452 | 1,575 | 1,810 | 2,112 | 2,309 | 3,003 | 1,276 |
| Med Parmasi Group | 0 | 1,824 | 1,645 | 2,094 | 2,610 | 2,282 | 1,474 | 1,185 |
| Vit Georgia Parmi | 2,523 | 1,804 | 753 | 743 | 1,270 | 912 | 1,006 | 1,023 |
| Medimex | 2,002 | 1,299 | — | — | — | — | — | — |
| Sando Pharma | 0 | 4,272 | 4,761 | 5,363 | 5,621 | 4,936 | 1,341 | — |
Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.
Peer coverage varies by year — FY2017, FY2019–FY2024 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.
Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.